Compounds useful in inhibiting human trefoil factor 3

A compound of formula I:

• wherein:
• R1 represents CN or Heta, which latter group is unsubstituted or substituted by halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C3-6 cycloalkyl, which latter four groups are unsubstituted or substituted by one or more substituents selected from halo, OH and NH2;
• R2 and R3 independently represent H, C(O)R7, S(O)x′R7′, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C3-6 cycloalkyl, which latter four groups are unsubstituted or substituted by one or more substituents selected from halo, OH and NH2;
• or
• R1 and R2 and/or R3, together with the atoms they are attached to, form a heterocyclic or heteroaromatic ring system having from 9 to 10 atoms in the ring system, which ring system is unsubstituted or substituted by one or more groups selected from ═S, ═O, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, aryl, or Hetb, which latter six groups are unsubstituted or substituted by one or more substituents selected from halo, OR8 and NR9R10;
• each R4 independently represents halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, (which latter four groups are unsubstituted or substituted by one or more substituents selected from halo, OH and NH2), OR11, or NR12R13,
• each R5 independently represents halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, (which latter four groups are unsubstituted or substituted by one or more substituents selected from halo, OH and NH2), OR14, or NR15R16;
• each R6 independently represents halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, (which latter four groups are unsubstituted or substituted by one or more substituents selected from halo, OH, NH2, and ═O), OR17, or NR18R19;
• R7 and R7′ independently represent Hetc, aryl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C3-6 cycloalkyl, which latter five groups are unsubstituted or substituted by one or more substituents selected from aryl (which group is unsubstituted or substituted by one or more of C1-6 alkyl, alkoxy, halo, NO2, OH and NH2), alkoxy, C1-3 alkyl, Hetd, halo, OH and NH2;
• R8, R11, R14 and R17 each independently represent at each occurrence thereof H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C3-6 cycloalkyl, which latter four groups are unsubstituted or substituted by one or more substituents selected from halo, alkoxy, OH and NH2;
• R9, R10, R12, R13, R15, R16, R18, and R19 each independently represent at each occurrence thereof H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or C3-6 cycloalkyl, which latter four groups are unsubstituted or substituted by one or more substituents selected from halo, alkoxy, OH and NH2;
• Heta to Hetd independently represent, at each occurrence, a 5- or 6-membered heterocyclic or heteroaromatic groups containing one or more heteroatoms selected from O, S and N, which heterocyclic groups are optionally substituted by one or more substituents selected from ═O, ═S, halo, OH, C1-4 alkyl and C1-4 alkoxy, which latter two groups are optionally substituted by one or more substituents selected from halo, OH and NH2;
• A represents a 5- to 13-membered carbocyclic or heterocyclic ring system that is aromatic and/or non-aromatic;
• x is from 0 to 4;
• x′ is from 1 to 2;
• y is from 0 to 5;
• and
• z is from 0 to 5,
• or a pharmaceutically acceptable salt or solvate, or a deuteriated compound of the Formula I thereof;
• with the proviso that a compound of formula I excludes the following compounds: